Much attention has gone to Regeneron and the monoclonal antibody cocktail known as REGN-CoV2, especially given the investigational drug was recently given to POTUS at…
The COVID-19 vaccine candidate known as BNT162b2 may be getting closer to registration (e.g. approval) as the European Medicines Agency (EMA) has accepted the initiation…
Pfizer’s CEO Albert Bourla joined Martha Brennan with CBS Face the Nation. An interesting character, he’s not just the standard “company man.” The chief declared…
Daina Graybosch, a top life science research analyst at SVB Leerink covering Immuno-Oncology, recently communicated to investors that Pfizer and partner BioNTech was moving forward with a…
Thanks to a partnership with J Lewis Research, healthcare provider Foothill Family Clinic in Salt Lake City, Utah, is conducting two Phase 3 clinical trials for COVID-19…
TrialSite recently reported on privately-held Aventiv Research Inc. as the only trial site organization in this part of Central Ohio to commence inoculating patients with the…
“Project Lightspeed” is coming to University Hospitals Cleveland Medical Center (UH) to conduct the pivotal Phase 2/3 global clinical trial sponsored by Pfizer (NYSE:PFE) and…
The Project Lightspeed initiative has come to Nashville, Tennessee. Clinical Research Associates, a trial site organization was selected by Pfizer to participate in the Phase 3…
New Haven, Connecticut, like many American cities, represents a multiplicity of reality exemplifying economic, social, cultural, and demographic diversity—that can manifest in chasms between those…
Independently-owned Columbus Ohio-based Aventiv Research was selected by the Pfizer/BioNTech “Project Lightspeed” program to participate in the Phase 2/3 clincial trial to test the RNA-based…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
